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Background: High-throughput omics technologies such as microarrays and next-generation sequencing (NGS) have
become indispensable tools in biological research. Computational analysis and biological interpretation of omics data can
pose significant challenges due to a number of factors, in particular the systems integration required to fully exploit and
compare data from different studies and/or technology platforms. In transcriptomics, the identification of differentially
expressed genes when studying effect(s) or contrast(s) of interest constitutes the starting point for further downstream
computational analysis (e.g. gene over-representation/enrichment analysis, reverse engineering) leading to mechanistic
insights. Therefore, it is important to systematically store the full list of genes with their associated statistical analysis results
(differential expression, t-statistics, p-value) corresponding to one or more effect(s) or contrast(s) of interest (shortly termed
as ” contrast data”) in a comparable manner and extract gene sets in order to efficiently support downstream analyses
and further leverage data on a long-term basis. Filling this gap would open new research perspectives for biologists to
discover disease-related biomarkers and to support the understanding of molecular mechanisms underlying specific
biological perturbation effects (e.g. disease, genetic, environmental, etc.).
Results: To address these challenges, we developed Confero, a contrast data and gene set platform for downstream
analysis and biological interpretation of omics data. The Confero software platform provides storage of contrast data in a
simple and standard format, data transformation to enable cross-study and platform data comparison, and automatic
extraction and storage of gene sets to build new a priori knowledge which is leveraged by integrated and extensible
downstream computational analysis tools. Gene Set Enrichment Analysis (GSEA) and Over-Representation Analysis (ORA)
are currently integrated as an analysis module as well as additional tools to support biological interpretation. Confero is a
standalone system that also integrates with Galaxy, an open-source workflow management and data integration system.
To illustrate Confero platform functionality we walk through major aspects of the Confero workflow and results using the
Bioconductor estrogen package dataset.
Conclusion: Confero provides a unique and flexible platform to support downstream computational analysis facilitating
biological interpretation. The system has been designed in order to provide the researcher with a simple, innovative, and
extensible solution to store and exploit analyzed data in a sustainable and reproducible manner thereby accelerating
knowledge-driven research. Confero source code is freely available from http://sourceforge.net/projects/confero/.
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The development and application of high-throughput tech-
nologies in biological research has presented researchers
with unprecedented amounts of omics data. Management,
analysis and interpretation of such data still pose significant
challenges. A plethora of open-source software solutions
(e.g. caArray [1], MARS [2], BASE [3], EMMA [4], MIMAS
[5,6], TM4 [7], MADMAX [8], MiMiR [9], ExpressionPlot
[10] to name a few) are readily available for storage and
management of raw and preprocessed high-throughput
datasets and metadata. These solutions provide a data
management platform to facilitate the beginning of the ex-
perimental data analysis process. Depending on the com-
plexity of experimental designs, statistical analysis of high-
throughput data can involve a number of sophisticated
techniques and tools. In transcriptomics, the identification
of differentially expressed genes when studying effect(s)/
contrast(s) of interest constitutes the starting point for fur-
ther downstream computational analysis (e.g. gene over-
representation/enrichment analysis, reverse engineering,
network building, etc.) leading to biological interpretation
and mechanistic insights. While many research sites use
systems to manage raw and processed data they still do
not take advantage of a central downstream infrastructure
to store and further exploit analyzed data in an integrated
way. In this situation, the value of knowledge gained from
analyzed data is restricted to the specific study in which
these data were generated, whereas this knowledge could
be leveraged during analysis of other studies. Even with
the arrival of bioinformatics workflow management sys-
tems (e.g. Galaxy [11-13], GenePattern [14], Taverna [15]),
which facilitate reproducible analyses, these systems by
themselves do not provide the functionality necessary to
centrally manage and further utilize analyzed data. Cur-
rently, no open-source and free software solutions of this
kind exist to store, manage and leverage analyzed data and
provide an integrated platform for downstream computa-
tional analysis, knowledge acquisition and integration
leading to new experimental hypothesis generation. Inte-
gration of tools and development of such platforms are
important to assemble a systems biology computational
workflow supporting interpretation of complex biological
data [16].
Here we present an innovative and extensible solution
to store and exploit analyzed omics data for the purpose
of knowledge acquisition and biological interpretation.
Confero enables research sites to store and manage ana-
lyzed contrast datasets and identifier (ID) lists of interest
(e.g. gene lists extracted from research papers, diagnostic
gene signatures), automatically compute and store gene
sets from these contrast data and ID lists, and analyze data
to support biological interpretation. Confero includes a
local database for storage and management of data and
metadata as well as tools for downstream computationalanalysis and biological interpretation, including gene set
enrichment analysis (GSEA) and over-representation ana-
lysis (ORA) [17]. The Confero Functional Enrichment
Analysis module includes specialized tools to facilitate and
accelerate enrichment/over-representation analysis and
extraction and interpretation of results.
The overall goal and spirit of Confero is illustrated in
Figure 1. The left loop depicts the typical omics work-
flow from data generation, processing, and statistical
analysis followed by downstream computational analysis
and biological interpretation leading to new hypothesis
generation. With Confero in place a second loop is
added where statistical analysis results are automatically
processed and new a priori biological knowledge (e.g.
gene sets) is stored. This knowledge base grows with
new experimental and external data and is leveraged by
integrated tools for biological interpretation. The added
loop in the analysis workflow facilitates and accelerates
knowledge acquisition in biological research, for ex-
ample in areas such as biomarker and gene function dis-
covery, understanding of molecular mechanisms, and
cross-study comparison. The overall process drives and
enhances the experimental research lifecycle.
Implementation
As shown in the Figure 2, processing and analysis of omics
data involves a number of steps, from data acquisition and
transformation, quality control (QC) (e.g. outlier detec-
tion, batch effect correction, etc.), preprocessing and
normalization, and statistical analysis. According to the
experimental design and biological questions of interest,
statistical analysis (e.g. pairwise comparisons, multiple lin-
ear regression models) is performed to determine the ef-
fect(s) of interest (e.g. effect of treatment over time, over
dosage, interaction of both time and dose, using pairwise
comparison of treated and control samples, etc.) also
termed the contrast(s) of interest from a dataset.
A contrast corresponds to a quantitative estimate of the
differential effect between treatment and reference condi-
tions or more generally as defined by a contrast matrix
[18]. Linear models are generally used to estimate the co-
efficient(s) related to the contrast(s). The estimation of
contrast data including differential expression (e.g. most
often corresponding to coefficient(s) of the linear model),
t-statistics and p-value can be computed for any entity
(gene, protein, probe set, transcript, microRNA, etc.) using
the Bioconductor [19] limma [18] or samr [20] packages
or other statistical analysis methods [21,22].
The Confero platform enables one to 1) convert contrast
data coming from statistical analysis into a simple and
standard data format, 2) process contrast data and extract
gene sets, 3) store contrast data, gene sets and metadata,
4) process and store external ID lists of interest as gene
































Figure 1 Biological knowledge building process enabled by Confero which enhances the standard omics analysis workflow. The left
loop depicts the typical omics workflow from data generation, processing, and statistical analysis followed by downstream computational analysis
and biological interpretation leading to new hypothesis generation. With Confero in place a second loop is added where statistical analysis
results are automatically processed and new a priori biological knowledge in the form of gene set is stored. This database of knowledge grows
with new experimental and external data and is leveraged by integrated tools for biological interpretation of current and future studies. The
overall process drives and enhances the experimental research lifecycle.
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(e.g. Confero DB, MSigDB [17], GeneSigDB [23,24]),
and 6) facilitate subsequent downstream analysis with a
variety of data transformation and export tools. Confero
runs as a standalone system and, as shown in Figure 3,
all platform modules are also integrated with the Galaxy
workflow management system [11-13]. An overview of
all available Confero tools with high-level description is
summarized in the Additional file 1: Table S1.
Advantages and strengths of platform
The Confero platform can serve a variety of different re-
search areas, including biomarker and drug discovery,
diagnostics, clinical research, consumer products (e.g.
nutrition) or any area that performs omics experiments
and analyses. Incorporation of such a platform into a
research site’s analysis workflow provides a number of
advantages, including that Confero:
 Is open-source, freely installable, customizable, and
easily integrates into the Galaxy bioinformatics
workflow management system Stores, manages, and leverages analyzed omics data
 Enables traceable and reproducible data analysis
 Compiles new biological knowledge (extraction of
gene sets from contrast data and population of
Confero gene set database) that can be exported and
easily shared
 Leverages compiled biological knowledge to analyze
(e.g. GSEA or ORA) and support biological
interpretation of new contrast data
 Integrates public sources of a priori biological
knowledge (e.g. MSigDB, GeneSigDB)
 Enables dataset comparison, i.e. systems (in-vitro vs.
in-vivo), organisms (human vs. mouse), treatments
(interleukin 1 (IL-1) vs. tumor necrosis factor
(TNF)) in a platform-independent manner
 Enables further downstream data mining and
meta-analysis of compiled contrast and gene set
data, e.g. biomarker discovery, iterative gene set
refinement
 Enables incorporation of additional analysis modules
(e.g. SAM-GS [25], Running Fisher’s Exact Test
[26]) to extend Confero functionalities
Figure 2 (See legend on next page.)
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Figure 2 Confero platform overview. Depicts where Confero fits into a typical high-throughput transcriptomics analysis workflow. Contrast
data is fed into the platform after the statistical analysis step where it is then converted to idMAPS format and loaded using Confero tools.
Contrast data is automatically processed and stored and gene sets are extracted. Data can be analyzed for gene set enrichment and results can
be used in other Confero tools or exported for other analyses.
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The Confero platform currently supports two types of
data input. The first type corresponds to the contrast
data resulting from statistical analysis (e.g. microarray or
NGS RNA-seq gene expression, microRNA expression,
etc.) and the second type can be a simple list of identifiers
(e.g. probe set, gene, microRNA, gene symbols, etc.)
processed and imported into the Confero database as
external gene sets.
idMAPS file format for contrast data
To support any type of statistical analysis approach, it was
necessary to devise a comprehensive yet straightforwardFigure 3 Screenshot of Confero platform integrated in Galaxy. Confer
command line. However, for non-programmatic users and to provide flexib
shows three main frames: 1) the first frame on the left contains all Confero
IMPORT), manage and export data from Confero (DATA MANAGEMENT AN
ENRICHMENT ANALYSIS MODULE); 2) the second frame in the middle gene
results once the job is done; 3) the third frame on the right contains all the
saved and the user can investigate the results of the analysis at any time. T
that have an account in Galaxy.file format to represent statistical analysis results. In
addition, as Confero requires and leverages various
important metadata describing input datasets, it was also
necessary that the file format support encoding and pass-
ing of such metadata from the upstream workflow in a
comprehensive yet independent manner. For this purpose,
the idMAPS file format was designed to represent the stat-
istical analysis results of omics experiments including
experimental and analysis metadata in fields present in the
header of the idMAPS file (e.g. dataset name and de-
scription, contrast names, source ID type, etc.). A util-
ity Confero Galaxy tool, Convert LIMMA/SAMR Object
(R object imported via the Upload LIMMA/SAM R Objecto platform is a standalone application that can be used via the
ility, Confero platform has been integrated into Galaxy. The window
tools (also see Additional file 1: Table S1) to import data (DATA
D EXPORT), run GSEA or ORA and manage results (FUNCTIONAL
rally displays the web page with the menu when selecting a tool, and
history of actions/results performed during an analysis. This history is
he user has also the possibility to share the history with other users
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samr R object into an idMAPS file with appropriate
header information which can then be used as input for
the Confero Galaxy Submit Contrast Dataset tool. During
the idMAPS file import, metadata are parsed and stored
in the Confero database together with contrast data and
gene sets. An example of the idMAPS file format is shown
in Additional file 2.Identifier list file format for external gene sets
In addition to supporting contrast data input, Confero
also accepts identifier (ID) lists. An example of an ID list
is shown in Additional file 3. This simple file format is a
single data column of source IDs with the same Confero
metadata file header as in the idMAPS data format.Data import, processing and storage
As shown in Figure 3, idMAPS contrast datasets and ID
lists are submitted for processing and loading into the
Confero database using the Confero Galaxy submission
tools Submit Contrast Dataset and Submit Gene Set, re-
spectively, or via the Confero application programming
interface (API). Confero utilizes a comprehensive and
robust idMAPS and ID list parser and data integrity
checker which, during data processing and submission,
will notify users of any problems with their input file.Input data identifier (ID) mapping and collapsing
methodology
Input idMAPS and ID list data files can use a variety of
different source ID types, such as Affymetrix probe set
IDs, HUGO gene symbols, and Entrez Gene IDs. To com-
pute gene sets from such data, Confero uses the latest
NCBI Entrez Gene [27] annotations to map data to a
single gene-centric ID space. For this purpose, a novel and
robust ID mapping and collapsing algorithm was devel-
oped and includes the following features:
 Source ID-to-multiple Entrez Gene ID mappings are
fully supported and handled robustly
 Entrez Gene RefSeq status information is leveraged
to determine best mapping genes
 Gene symbol synonyms are supported and properly
mapped
 Multiple available collapsing strategies
 Summary report of procedure is generated and
stored in Confero database along with each dataset
and viewable via the Confero web application
A detailed flowchart describing the Confero ID mapping
and collapsing algorithm is shown in Additional file 4:
Figure S1.Gene set extraction methodology
As prior biological knowledge, a gene set is information
commonly utilized to assess enrichment (e.g. GSEA or
ORA) of co-regulated genes representative of a specific
biological process, pathway, chromosomal location, etc.
In the context of contrast data, a gene set corresponds
to a set of genes characteristic of an effect of interest.
During the Confero submission process, once input
data files have completed the ID mapping and collaps-
ing procedure, the Entrez Gene ID-based processed data
undergo a novel and robust procedure to extract and
store gene sets. The Confero platform builds a gene set
database from all imported data that is then leveraged
by Confero tools.
Each contrast in a dataset has at least three gene sets
automatically generated and named with the following
suffixes: the UP (up-regulated genes), DN (down-regulated
genes), and AR (all-regulated genes) gene sets. AR gene
sets are a special type used to represent the global re-
sponse of a system to the applied stimulus. The
Confero platform provides the user complete and
granular control over how each gene set is extracted.
As shown in Additional files 2 and 3, special parame-
ters can be provided in the idMAPS metadata header
to override default behavior and specify to the algo-
rithm exactly how to proceed. One can also specify to
Confero not to create gene sets for a certain contrast
(e.g. an intercept coefficient of a linear model) or even
for an entire dataset. Different gene set extraction
parameters can be specified for each contrast, such as
minimum and maximum size thresholds, P (signifi-
cance level, p-value, or false discovery rate (FDR)), A
(average signal) and M (estimated effect of interest, e.g.
log2 fold change) value thresholds, and even specific
desired gene set sizes. A detailed flowchart describing
the Confero gene set extraction algorithm is shown in
Additional file 5: Figure S2.Data management and export
The Confero platform provides an integrated web applica-
tion to view and manage data and metadata in the
Confero database. The web application operates independ-
ently of Galaxy but for convenience Confero also embeds
it into the Galaxy user interface as the View and Manage
Data tool. The web application also allows users to export
source data, processed data, generated gene sets and data
processing reports via the user interface or via the Confero
API. Confero also provides an Extract Gene Set Matrix
Galaxy tool to generate and export boolean gene set-to-
gene membership matrices and an Extract Gene Set
Overlap Matrix tool to extract gene set-to-gene set over-
lap matrices (i.e. number/percentage of shared genes
between two gene sets).
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interpretation
Functional enrichment analysis is commonly used to
support biological interpretation of gene expression
data. The Confero platform currently supports: 1) over-
representation analysis (ORA) and 2) gene set enrich-
ment analysis (GSEA), a commonly used and powerful
approach for biological data interpretation [17]. An
important advantage of GSEA is that full contrast data
(e.g. genome-wide expression profiles) can be analyzed
in a p-value threshold independent manner unlike other
approaches such as ORA.
Both approaches require as inputs a gene list (partial list
for ORA and full ranked list for GSEA) and a collection of
gene sets used as a priori knowledge. A targeted choice of
gene sets selected for analyses can provide insight to spe-
cific biological questions. We developed a fully integrated
Functional Enrichment Analysis module which can seam-
lessly use Confero contrast data and gene sets (Figure 3;
Additional file 1: Table S1). The code and reporting for
ORA was developed internally. For GSEA, Confero usesFigure 4 Screenshot of the report following importing and processin
Galaxy. The report shows 1) whether contrast data have been correctly im
collapsing process reported at the top of the document (“Check/Map/Colla
have been automatically extracted from each contrast and stored (UP, DN,
(see also Figure 5), 169, 105 and 274 most significantly up- , down- and all-
UP, DN and AR from the contrast data “Estro10” (comparison of gene exprethe Broad Institute’s GSEA Java implementation and re-
sults reporting [17]. Importantly, Confero dynamically
customizes the GSEA results report and provides several
tools to accelerate downstream analysis of results. The
Functional Enrichment Analysis module includes the fol-
lowing tools:
 Create Ranked or DEG Lists: gene lists can be easily
generated from contrast data in the Confero
database using the statistic (S, moderated t-statistic)
or differential expression value (e.g. M, log2 fold
change) data as the rank metric for GSEA, or using
the significance level (P) for ORA (further leveraged
to filter the gene list while using the Analyze Data
functionality described below).
 Analyze Data: ranked and DEG (p-value threshold
defined by the user) lists can be analyzed for gene
set enrichment/over-representation against
dynamically definable Confero gene set collections
using annotation filters as well as the latest MSigDB
and GeneSigDB gene set collections. The selectiong of the Bioconductor estrogen contrast data in Confero using
ported and processed (several checks during the mapping and
pse Contrast Dataset Report”), 2) information on the gene sets that
and AR gene sets) in the Confero DB (“Gene Set Report”). As example
regulated genes (FDR<0.05) were respectively extracted as gene sets
ssion levels of estrogen vs control samples collected at 10h).
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(Hypergeometric Test)) conditions the Galaxy menu
displayed to choose specific parameters for the
analysis.
 Extract Leading Edge Matrix: leading edge matrices
of various types can be extracted from a GSEA
result; the leading edge matrix is comprised of
GSEA leading edge genes (in rows) from all gene
sets in the result (in columns) passing a specified
FDR threshold with rank metric score, rank in list,
or boolean membership values as the matrix fields.
 Extract Results Matrix: a comprehensive results
matrix with user selected output columns can be
extracted from one or more functional enrichment
analysis results.
In summary, the Confero Functional Enrichment
Analysis module allows biologists to compare datasets in
a contextual manner (e.g. by organism, cell/tissue type,
stimulus type, experimental system, etc.) and to more effi-
ciently identify underlying molecular mechanisms based
on biological interpretation of results.Figure 5 Screenshot of the Estrogen contrast dataset entry in the Confer
Manage Data” tool is selected in the toolbox (left frame) and the appropriate co
information on the contrast dataset at the top (e.g. “BMC_Bioconductor_Estroge
associated gene sets at the bottom (e.g. “BMC_Bioconductor_Estrogen_PW_[Est
files can be saved locally upon needs.Results and discussion
Case study: estrogen bioconductor dataset
To provide an example of the application of the Confero
platform, we have used the estrogen expression dataset
available from the Bioconductor web site [28]. In this 2×2
factorial experiment, MCF7 breast cancer cells were
treated with estrogen for 10 or 48 hours. The experimental
factors were as follows: “estrogen treatment” with condi-
tions present or absent, and “time” also with two condi-
tions 10 or 48 hours. Following extraction, RNA was
hybridized on to Affymetrix HG_U95Av2 microarrays.
The purpose of this study was to identify early and late
biological processes driven by estrogen putative direct
target genes for early response, while for later events the
response might be driven by more downstream targets in
the molecular pathway.
Raw data (CEL files) were preprocessed and normalized
as described in the Confero platform overview schema
(Figure 2). The Bioconductor limma package was used to
compute contrasts corresponding to the effect of estrogen
at 10 (early) and 48 (late) hours (estrogen treatment vs.
control comparison for each time point). Additionally, theo DB. To access a database Estrogen Contrast data entry, the “View and
ntrast dataset name can be chosen in the available list. The entry contains
n_PW”), contrasts (e.g. “BMC_Bioconductor_Estrogen_PW_[Estro10]”) and
ro10]_UP”). Details and data files can be accessed via the hyperlinks. Data
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puted to directly investigate the differential effect of estro-
gen treatment at 10 and 48 hours. The output limma R
object from the eBayes R function (see Additional file 6)
was imported into Galaxy using the Confero Upload
LIMMA/SAM R Object tool. Data for each contrast, in-
cluding log2 fold changes (M) between control and estro-
gen treatment conditions, probeset average signal (A),
moderated-t statistic (S), and associated FDR (P), were
automatically extracted from the R object and converted
into idMAPS format using the Confero Convert LIMMA/
SAM R Object tool (see Figure 3, Additional file 2 and
Additional file 1: Table S1). The idMAPS file was then
imported into the Confero database using the Submit
Contrast Dataset tool (Figure 3 and Additional file 1:
Table S1). To note, it is also possible to directly import an
already formatted idMAPS file into the Confero platform
without using the Convert LIMMA/SAM R Object tool
(Figure 3 and Additional file 1: Table S1). A summary
report shows how the contrast dataset was processed and
imported as well as information on the gene sets (UP, DN,
and AR) extracted and stored for each contrast (Figure 4).
In this example, 169, 105 and 274 most significantly up-,Figure 6 Screenshot of the Estrogen gene set entry in the Confero DB. C
[Estro10]_UP) enables to access detailed information such as the rank of the gen
and description.down- and all-regulated genes (FDR<0.05) were respect-
ively extracted as gene sets UP, DN and AR from the con-
trast data “Estro10” (comparison of gene expression levels
of estrogen vs control samples collected at 10h). Stored in
Confero database, these gene sets represent gene expres-
sion perturbation fingerprints of estrogen effect on MCF7
at 10h and could be further leveraged as a priori know-
ledge to analyze and compare new datasets. Contrast data
and gene sets derived from the Estrogen data analysis can
be accessed and visualized using the View and Manage
Data tool as shown in Figures 5 and 6.
To unravel biological processes/pathways regulated by
estrogen at the early and late time points, GSEA was
performed on the imported contrast data from the
estrogen dataset. The Confero Create Ranked or DEG Lists
tool was used to generate a ranked genome-wide differen-
tial expression profile for each contrast of the dataset
using the moderated-t statistic data column (S) as rank-
ing metric. With these ranked profiles (i.e. “Estro10”,
“Estro48”, and “Interaction”) as input, the Confero
Analyze Data tool was used to set up options and parame-
ters to perform GSEA or ORA (Figures 3, 7 and 8). As an
example of GSEA used in the context of this study case,licking on a gene set hyperlink (e.g. BMC_Bioconductor_Estrogen_PW_
es extracted from the contrast, the Entrez gene ID, the gene symbol
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tute was selected as a priori knowledge. Over time,
Confero DB is automatically populated by gene sets as
new contrast data or manually curated gene sets are
imported into the database. Therefore, having the ability
to filter gene sets in a specific manner is crucial to have
the possibility to address specific biological questions. A
filtering functionality is currently available in the Analyze
Data tool and will be enhanced in future developments
(Figures 3 and 7; Additional file 1: Table S1). The gener-
ated GSEA and ORA results for each contrast are directly
accessible via the Galaxy user interface (Figures 9 and 10).
The investigation of GSEA results through the report on
the web is generally a long and tedious process to interpret
the results. Indeed, researchers typically have to manually
analyze the results sifting through the report for each
contrast and drilling down to each gene set to access the
associated leading edge genes. Therefore, to facilitate and
accelerate analyzing results and biological interpretation,
the Confero Extract Results Matrix tool was used to ex-
tract all related GSEA results into a tab-delimited spread-
sheet file (see Additional file 7). The user has the flexibilityFigure 7 Screenshot of the Confero Analyze Data Tool (GSEA). Selectin
parameters for GSEA in the Galaxy menu. Confero DB is automatically popu
sets are imported into the database. Therefore, having the ability to filter/s
address specific biological questions. A filtering/searching functionality (ena
specific filters or free text expression) is currently available in the Analyzed Dto select which GSEA results to be extracted. The file
contains normalized enrichment scores (NES), NES-
associated false discovery rate (FDR) and eventually ranks
at which NES is observed in the ranked gene list for all an-
alyzed Estrogen contrast data (i.e. “Estro10”, “Estro48”,
and “Interaction”). When interpreting GSEA results, it is
generally important to identify which genes contribute the
most to the enrichment of significant gene sets. To deter-
mine this, the Confero Extract Leading Edge Matrix tool
was used to extract all leading edge genes from gene sets
having FDR values below a user-defined threshold (default
value of 0.05) into a single output matrix (see Additional
file 8). This customizable output matrix can contain bool-
ean values, moderated-t statistic values (see Additional file
8), or gene rank. This file provides to the biologist more
granular molecular insights for interpretation by identify-
ing genes which contribute the most to significant enrich-
ment of observed perturbed biological processes.
Overall, the result files generated by the Confero plat-
form tools enable more rapid and efficient biological in-
terpretation of data. Indeed, the GSEA results matrix
can be directly leveraged to identify significant gene setsg the analysis algorithm “GSEA Preranked” enables to select specific
lated by gene sets as new contrast data or manually curated gene
earch gene sets in a specific manner is crucial to have the possibility to
bling to search gene sets by organism, tissue/cells, stimulus using
ata tool and will be enhanced in future developments.
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across contrasts similarly to Figure 11. Grouping gene
sets per biological processes and investigating the lead-
ing edge genes associated to significantly enriched gene
sets enables to rapidly interpret biological events at the
molecular level and raise new hypothesis that could fur-
ther be experimentally verified. As shown in 11, the re-
sults highlight that processes corresponding mainly to
cell cycle and metabolism were activated in MCF7 cells
exposed to estrogen. The pattern of gene set enrichment
over time seemed to indicate that the proportion of
MCF7 cells in different phases of the cell cycle diverged
at early and late time points. Indeed, enrichment of
genes representative of the G1 and S-phases were more
important at 10 hours, whereas enrichment of genes
involved in G2 and M-phases was predominant at 48
hours. Therefore, it was possible to follow the enrich-
ment profile over time for genes implicated in processes
coupled to growth and division of cells: activation of
protein synthesis machinery, lipid and sugar metabolism
to provide energy to the cell, nucleotide metabolism re-
quired for DNA replication, amino acid metabolism for
protein synthesis, and decrease of cell-cell and extracel-
lular interaction as well as cytoskeleton function, whichFigure 8 Screenshot of the Confero Analyze Data Tool (ORA). Selectin
specific parameters for ORA in the Galaxy menu. MSigDB gene set collectiois a phenomenon characteristic of cells under prolifera-
tion. Similar observations have been reported by other
studies investigating gene expression profiles of MCF7
exposed to estradiol [29,30]. Only at the later time point
(48 hours), genes involved in oxidative phosphorylation
and TCA cycle were highly enriched. This observation
might suggest that either cell mitosis is accompanied by
mitochondria biogenesis [31], or that estrogen regulates
the transcription of those genes. Independent studies
seem to support the latter hypothesis. Indeed, estradiol
has been shown to enhance the transcript levels of mito-
chondrial genome-encoded genes in several cell types
such as MCF7 [32,33]. In hepatocytes, this effect was ac-
companied by an increase of the mitochondrial respira-
tory chain activity [33].
Galaxy integration and workflows
The Confero platform functions as a standalone system
and, as shown in Figure 3, can also be fully integrated into
the Galaxy reproducible research framework which allows
sites to easily incorporate Confero into their existing ana-
lysis and knowledge acquisition workflows. Galaxy offers
the possibility to chain as well as parallelize, in a custom-
ized and flexible way, Confero tools via Galaxy’s workflowg the analysis algorithm “ORA (Hypergeometric Test)” enables to select
ns are available for ORA.
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http://www.biomedcentral.com/1471-2164/14/514framework. For example, the Confero Functional Enrich-
ment Analysis module tools can be connected in a work-
flow to efficiently analyze data and extract results in
parallel.
Public data update and confero database reprocessing
Vendor technology platform and public Entrez Gene in-
formation and annotations update frequently and since
all Confero gene sets are computed utilizing this infor-
mation over time the Confero gene set database would
become stale and out-of-date. In addition, if a site chose
to change Confero platform configuration parameters
for data processing and/or gene set extraction it would
be important that this change propagate not only to
new data but to all existing data stored in the Confero
database. An important and powerful management fea-
ture of the Confero software platform is the ability to
automatically download and update all relevant and sup-
ported vendor technology platform and public gene infor-
mation and then, using this information, fully reprocess all
data contained in the Confero database utilizing current
desired configuration parameters. Processed datasets are
tagged with processing date and annotation build versionsFigure 9 Screenshot of a GSEA report in Galaxy. GSEA has been perfor
using the complete MSigDB C2 gene set collection. The users can navigate
the web page (middle frame).to ensure analysis reproducibility. This functionality is
provided by a management program within the Confero
distribution.
The Confero distribution currently supports Affymetrix,
Illumina, and any NCBI GEO-derived microarray platform
as well as all HUGO gene symbols. The management pro-
gram automatically downloads source annotation files and
Entrez Gene information to generate new mapping files.
Adding support for other technology platforms (e.g.
Exiqon, Nimblegen, etc.) is also possible. For NGS plat-
forms, currently gene level data and analysis is supported.
Management features and application programming
interface (API)
Confero provides a number of useful management func-
tionalities neatly packaged as server-side programs for
administrators and software platform managers. This
includes programs to perform the following tasks:
 Process and submit batches of contrast datasets or
ID lists
 Download, process, and load the latest vendor
annotations and Entrez Gene information tomed with the “BMC_Bioconductor_Estrogen_PW_[Estro10]” contrast
in the GSEA report to investigate the results using the hyperlinks of
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http://www.biomedcentral.com/1471-2164/14/514generate new Confero source-to-Entrez Gene ID
mapping files and fully reprocessing all Confero
database data
 Control the Confero embedded web server and
application
 Export the entire Confero gene set database with
annotations
The API currently provides functions to export different
data from the platform.
Comparison to existing software
The Confero platform provides a unique set of function-
alities and differs from existing publicly available soft-
ware in a number of key aspects. Currently, there are
other systems, such as Cistrome [34] and the Genomic
HyperBrowser [35], which also have Galaxy integration.
In contrast with Confero these systems are focused on
certain types of omics data types and are not provided
as a software distribution that can be installed locally to
work with private as well as public data. Other systems
such as TM4 [7,36], provide some similar analysisFigure 10 Screenshot of ORA output in Galaxy. ORA has been perform
using the complete MSigDB C5 gene set collection. The users can visualize
as a tab-delimited txt file. The file contains 4 columns corresponding to ge
gene set, the hypergeometric test p-value and the adjusted p-value (FDR).functionalities such as GSEA. Yet these systems are only
all-in-one standalone solutions, not integrated with popu-
lar workflow management systems like Galaxy, and do not
process imported data to build a database of a priori bio-
logical knowledge that is then leveraged by system tools.
Finally, ArrayExpress and GEO, the two major public re-
positories, provide tools [37-41] to mine data across a sub-
set of curated and preprocessed studies in their databases.
However, such tools are clearly limited to what is available
in their systems and cannot be locally installed to work
with private data. In addition, many of these systems start
with raw/preprocessed data and perform automated statis-
tical analysis, which in Confero a deliberate design choice
was made to allow each site the freedom to have custom-
ized statistical analysis approaches appropriate for each
experimental design and relevant biological questions.
Conclusions
Storage and exploitation of analyzed omics data is a cru-
cial component of a research site’s analysis workflow as
it enables acquisition of new biological knowledge
which facilitates interpretation of data. However, theseed with the “BMC_Bioconductor_Estrogen_PW_[Estro10]” contrast
the ORA output in Galaxy (middle frame) and easily export the results
























GENE SET NAME 10h 48h I
BIOCARTA_G1_PATHWAY 1.57 1.30 -1.34
REACTOME_GTP_HYDROLYSIS_AND_JOINING_OF_THE_60S_RIBOSOMAL_SUBUNIT 1.77 1.17 -0.97
REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQUENTLY_THE_43S_COMPLE 1.69 1.15 -0.96
REACTOME_FORMATION_OF_A_POOL_OF_FREE_40S_SUBUNITS 1.67 1.18 -0.83
KEGG_RIBOSOME 1.71 1.16 -0.92
BIOCARTA_EIF_PATHWAY 1.65 1.00 -1.48
REACTOME_TRANSLATION_INITIATION_COMPLEX_FORMATION 1.59 1.13 -0.85
REACTOME_PEPTIDE_CHAIN_ELONGATION 1.73 1.06 -1.03
REACTOME_TRANSLATION 1.71 1.10 -0.91
REACTOME_VIRAL_MRNA_TRANSLATION 1.71 1.15 -0.98
REACTOME_AMINO_ACID_TRANSPORT_ACROSS_THE_PLASMA_MEMBRANE 1.66 1.38 -1.32
REACTOME_AMINO_ACID_AND_OLIGOPEPTIDE_SLC_TRANSPORTERS 1.50 1.23 -1.20
KEGG_GLYCINE_SERINE_AND_THREONINE_METABOLISM 1.56 1.38 -0.69
REACTOME_G1_S_TRANSITION 2.80 2.65 1.24
REACTOME_SYNTHESIS_OF_DNA 2.89 2.67 1.30
REACTOME_DNA_REPLICATION_PRE_INITIATION 2.71 2.65 1.27
REACTOME_DNA_STRAND_ELONGATION 2.75 2.73 -1.45
REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX 2.57 2.47 -1.45
REACTOME_E2F_MEDIATED_REGULATION_OF_DNA_REPLICATION 2.47 2.42 -1.53
BIOCARTA_G2_PATHWAY 1.65 1.54 1.40
REACTOME_G2_M_CHECKPOINTS 2.70 2.59 1.25
REACTOME_CHOLESTEROL_BIOSYNTHESIS 1.97 2.07 1.41
KEGG_BIOSYNTHESIS_OF_UNSATURATED_FATTY_ACIDS 1.93 1.93 0.95
REACTOME_STEROID_METABOLISM 1.65 1.54 -0.76
REACTOME_GLUCOSE_TRANSPORT 1.65 1.81 0.91
REACTOME_REGULATION_OF_GLUCOKINASE_BY_GLUCOKINASE_REGULATORY_PROTEIN 1.64 1.79 0.87
KEGG_PENTOSE_PHOSPHATE_PATHWAY 1.62 1.55 0.68
KEGG_GALACTOSE_METABOLISM 1.55 1.51 -0.77
REACTOME_METABOLISM_OF_VITAMINS_AND_COFACTORS 1.64 1.54 0.83
KEGG_PYRIMIDINE_METABOLISM 2.66 2.41 -1.26
REACTOME_PYRIMIDINE_METABOLISM 2.13 1.91 -1.38
REACTOME_METABLISM_OF_NUCLEOTIDES 2.63 2.41 -1.39
KEGG_CYSTEINE_AND_METHIONINE_METABOLISM 1.71 1.66 -0.59
REACTOME_TRNA_AMINOACYLATION 1.93 1.72 -1.07
KEGG_AMINOACYL_TRNA_BIOSYNTHESIS 1.79 1.58 -1.09
REACTOME_CYTOSOLIC_TRNA_AMINOACYLATION 2.07 1.76 -1.26
REACTOME_GLYCOLYSIS 1.35 1.54 1.36
11.1SISENEGOENOCULG_SISYLOCYLG_GGEK 1.67 1.34
82.1MSILOBATEM_ESOCULG_EMOTCAER 1.67 1.42
KEGG_PYRUVATE_METABOLISM 1.47 2.00 1.46





KEGG_ADHERENS_JUNCTION -1.60 -1.80 1.15
36.1-SNOITCARETNI_SNOITCNUJ_SNEREHDA_EMOTCAER -1.76 -0.81
28.0-NOITCARETNI_ROTPECER_MCE_GGEK -1.74 -1.86
KEGG_FOCAL_ADHESION -1.15 -1.72 -1.12
BIOCARTA_MYOSIN_PATHWAY -1.53 -1.80 -1.05
23.1-NOTELEKSOTYC_NITCA_FO_NOITALUGER_GGEK -1.76 -1.04
REACTOME_AXON_GUIDANCE -1.14 -1.69 -1.20
45.0-STNEVE_GNILLANGIS_Q_AHPLA_G_EMOTCAER -1.66 -1.54
KEGG_AXON_GUIDANCE -1.30 -1.67 -0.99
REACTOME_MAPK_TARGETS_NUCLEAR_EVENTS 67.1-SESANIK_PAM_YB_DETAIDEM_ -1.82 0.80
63.1-YAWHTAP_GNILANGIS_KPAM_GGEK -1.76 0.89
45.1-EDACSAC_RLT_NI_NOITAVITCA_SESANIK_PAM_EMOTCAER -1.74 0.95
BIOCARTA_MAPK_PATHWAY -1.54 -1.70 0.74
BIOCARTA_P38MAPK_PATHWAY -1.47 -1.70 -0.94
KEGG_TIGHT_JUNCTION -1.49 -1.70 1.04
ST_JNK_MAPK_PATHWAY -1.78 -1.69 0.91
REACTOME_MITOTIC_PROMETAPHASE 1.98 2.41 2.37
REACTOME_MITOTIC_M_M_G1_PHASES 2.45 2.70 2.10
REACTOME_CELL_CYCLE_MITOTIC 2.85 2.98 2.04
REACTOME_G2_M_TRANSITION 1.84 2.16 2.03
REACTOME_CENTROSOME_MATURATION 1.53 1.91 1.92
REACTOME_CYCLIN_A1_ASSOCIATED_EVENTS_DURING_G2_M_TRANSITION 1.88 2.07 1.92
REACTOME_CELL_CYCLE_CHECKPOINTS 2.73 2.68 1.64
REACTOME_FORMATION_AND_MATURATION_OF_MRNA_TRANSCRIPT 2.04 2.53 2.25
REACTOME_ELONGATION_AND_PROCESSING_OF_CAPPED_TRANSCRIPTS 2.13 2.60 2.19
REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA 2.45 2.68 2.00
KEGG_SPLICEOSOME 1.99 2.43 2.19
REACTOME_MRNA_SPLICING 2.36 2.63 2.19
REACTOME_MRNA_SPLICING_MINOR_PATHWAY 2.10 2.38 1.93
REACTOME_E2F_TRANSCRIPTIONAL_TARGETS_AT_G1_S 2.41 2.24 -1.90
KEGG_HUNTINGTONS_DISEASE 1.21 2.31 2.28
KEGG_OXIDATIVE_PHOSPHORYLATION 1.15 2.26 2.25
83.1NOITERCES_NILUSNI_FO_NOITALUGER_ESOCULG_EMOTCAER 2.24 2.25
KEGG_PARKINSONS_DISEASE 1.34 2.18 2.21
51.1MSILOBATEM_YGRENE_FO_NOITARGETNI_EMOTCAER 2.03 2.10
20.1ELCYC_ACT_ELCYC_ETARTIC_GGEK 1.89 1.96
REACTOME_PYRUVATE_METABOLISM_AND_TCA_CYCLE 1.14 1.85 1.63
KEGG_GLUTATHIONE_METABOLISM 1.36 1.74 1.64
KEGG_BUTANOATE_METABOLISM 1.09 1.73 1.61
REACTOME_CITRIC_ACID_CYCLE 0.91 1.72 1.84
KEGG_PROPANOATE_METABOLISM 0.96 1.62 1.69
BIOCARTA_PROTEASOME_PATHWAY 1.21 2.06 1.97
KEGG_PROTEASOME 1.48 2.00 1.69
KEGG_RNA_DEGRADATION 1.46 1.98 1.66
Estrogen effect
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Figure 11 Summary of Confero Bioconductor estrogen dataset GSEA results and leveraging of leading edge genes results from Export
Leading Edge Matrix tool. Grouping gene sets per biological processes and investigating the leading edge genes associated to significantly
enriched gene sets enables to rapidly interpret biological events at the molecular level and raise new hypothesis that could further be
experimentally verified. Red and green colors highlight normalized enrichment scores that are significantly enriched for up- or down-regulated
genes, respectively.
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http://www.biomedcentral.com/1471-2164/14/514needs are not met by the current open-source solutions
freely available to researchers. The Confero platform
has been built to provide an innovative, flexible and exten-
sible solution to store and leverage analyzed data and
build new a priori biological knowledge. In addition,
Confero enables cross-platform comparison of omics data
in a traceable and reproducible manner.
While GSEA or ORA provide a useful global overview
of the perturbed biological processes occurring during
an experiment, there are a number of potential methods
that can further utilize Confero data to gain a more
detailed understanding of underlying mechanisms. We
are currently developing additional integrated tools in
the following areas:
 Clustering module to group Confero data (e.g. gene
sets, genes, etc.) in order to highlight patterns of co-
regulation in experimental data
 Visualization module to provide integrated and easy-
to-use plotting functions (e.g. volcano plots) on
Confero results
 HomoloGene infrastructure and integration to
provide cleaner species-to-species translation during
gene set enrichment analysis
 Incorporation of additional analysis tools to provide
complementary approaches to GSEA for biological
interpretationAvailability and requirements
An overview of the Confero platform software architec-
ture is shown in Additional file 9: Figure S3. Confero is
written using the Perl [42] programming language and
requires Perl 5.12 or higher. To use the Convert
LIMMA/SAMR Object tool, an R version and the
Bioconductor limma and samr packages should be in-
stalled. The Confero platform requires a backend data-
base and MySQL [43] is currently supported. MySQL
5.0 or higher (5.1 and 5.5) have been fully tested and are
being used in production installations. Confero can be
installed on any UNIX like operating system (e.g. BSD,
Linux, etc.) and has been fully tested and used in pro-
duction using the Linux operating system. The docu-
mentation for the Confero command line interface
(CLI) is provided as Additional file 10 and is also avail-
able on SourceForge (http://sourceforge.net/projects/
confero/).The Confero distribution comes with an interactive
setup program to guide administrators through installa-
tion and configuration of the entire software platform
for a site. This includes automatic download and instal-
lation of dependencies, creation and initial population of
the database, Galaxy server integration, and automatic
download, processing and loading of all required refer-
ence data to begin using the platform. For Confero
terms of use and installation, you will have to refer to
the DISCLAIMER and INSTALL files provided with
Confero software freely available on http://sourceforge.
net/projects/confero/ and released under the GPLv2
license.
Additional files
Additional file 1: Table S1. Overview of tools available in Confero.
Additional file 2: Example of idMAPS file format from Bioconductor
estrogen dataset. The file format includes the following characteristics:
• Simple, tab-delimited file format with data column header row and file
header to encode metadata and other important user-defined
parameters relevant to data processing.
• The first data column always contains the source IDs for each data row.
Source IDs can come from any technology platform supported by
Confero, i.e. any platform where ID mapping data is defined.
• Data column header letters represent the important statistical analysis
results: M is the estimated effect of interest (e.g. log2 fold change), A is
the average signal, P is the significance level (p-value or false discovery
rate (FDR)), and S is the statistic (e.g. moderated t-statistic).
• Contrast data derived from the same statistical analysis (i.e. a contrast
dataset) are represented by repeating groups of data columns (e.g.
MAPSMAPSMAPS…) as a matrix in the same file.
• Data columns may be in any order (e.g. APSM, SAPM, MASP, etc.) as
long as they are in the same order for each contrast (e.g.
AMSPAMSPAMSP…).
• Certain data columns may be omitted if they do not exist. The
minimum requirements are the data column M and that each group
within a dataset must have the same data column(s). Additional arbitrary
data columns not used by Confero may be included for each contrast
which are stored and passed through during data processing.
Additional file 3: Example of ID list file format using Gene
Ontology (GO) Inflammatory Response biological process. The file
contains header lines that provides a description of the gene list
(“gene_set_desc”), indicates the type of ID used (Entrez gene ID can also
be used) (“id_type”) and the organism from which the gene list is
derived from.
Additional file 4: Figure S1. Confero dataset ID mapping and
collapsing algorithm flowchart. This figure depicts the steps enabling to
go from the original idMAPS data matrix to a mapped and collapsed
data matrix ready for downstream GSEA or other analysis which requires
no multiple probesets per gene (Gene centric).
Additional file 5: Figure S2. Confero gene set extraction algorithm
flowchart. The figure depicts the steps to extract up- (UP), down- (DN)
and all- (AR) regulated genes from mapped and collapsed contrast data
leading to the creation of new gene sets stored in Confero DB.
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http://www.biomedcentral.com/1471-2164/14/514Additional file 6: R limma object from Bioconductor estrogen
dataset pairwise comparison statistical analysis.
Additional file 7: Bioconductor estrogen dataset MSigDB canonical
pathways GSEA results matrix from Extract Results Matrix tool. All
GSEA results for the analysis of several contrasts can be extracted in a
single file using the Extract Results Matrix tool.The columns respectively
correspond to gene set name, normalized enrichment scores (NES), NES-
associated false discovery rate (FDR) and rank (for which the maximum
enrichment score is identified in the ranked gene list) for the selected
analyzed contrasts. The tool provides flexibility to select the contrasts and
GSEA result parameters to be exported.
Additional file 8: Bioconductor estrogen dataset 10 hour time point
MSigDB canonical pathways GSEA leading edge matrix from
Confero Extract Leading Edge Matrix tool. When interpreting GSEA
results, it is generally important to identify which genes contribute the
most to the enrichment of significant gene sets. The Confero Extract
Leading Edge Matrix tool was designed to extract all leading edge genes
(as rows) from gene sets (as columns) having FDR values below a user-
defined threshold (default value of 0.05) into a single output matrix. This
customizable output matrix can contain boolean values, moderated-t
statistic values (current view), or gene rank.
Additional file 9: Confero software architecture schematic diagram
showing the various platform components and how they integrate
with each other. Users currently interact with Confero via the web
browser or command line interface (CLI). Users execute Confero tools via
the Galaxy user interface or CLI commands and can view and manage
data in Confero via the Confero web application. Users can leverage
Galaxy functionalities with Confero tools such as workflow building and
execution, parallel and asynchronous job processing, and sharing and
publishing of results. Confero administration is performed using
management scripts which update annotations from NCBI Entrez Gene,
Affymetrix, Illumina, Agilent, and GEO and then can reprocess Confero DB
data using updated annotations.
Additional file 10: Confero command line interface documentation
including examples. Confero can be used via Galaxy web interface or
command line interface for a programmatic usage of the platform.
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